The continued joint goal is to establish FloridaWild as a "Centre of Excellence" to obtain and evaluate more clinical data for different animal species.
We are, along with FloridaWild, also having ongoing discussions with MVP - Mission Veterinary Partner - regarding installing the vetIQure™ device on other clinics within the organisation. MVP is a veterinary services organisation founded in 2017 and is a group of around 350 veterinary clinics and hospitals across the States.
"We are happy to announce that today we received confirmation that FloridaWild will fulfil their commitment to purchase the vetIQure™ device after a six-month clinical service agreement. We are delighted to have FloridaWild as part of our collaboration in testing the efficacy of TSE and assisting in the growth process of expanding our technology across North America." - says Danny Edward Nesrallah, Head of Business Development North America for Vetiqure AB
"We have been very impressed with our patient outcomes over the last 6 months and are pleased to be able to permanently provide our patients access to this therapy. We have alsobeen pleased with the support we continue to get from Danny Nesrallah and his team, as they unfailingly provide any medical or technical support we require. Vetiqure has been a partner in ensuringethical patient selection and thorough data collection,which solidifies my faith in this company and its commitment to research and improving cancer care. We are pleased to have their support as we provide this therapy and proud to play a role in contributing to their work."- says Dr Pamela Schrager, Medical Director, FloridaWild Veterinary Hospital